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CattleCardiomyopathies are severe degenerative disorders of the myocardium that lead to heart failure. During the
last three decades bovine dilated cardiomyopathy (BDCMP) was observed worldwide in cattle of Holstein–
Friesian origin. In the Swiss cattle population BDCMP affects Fleckvieh and Red Holstein breeds. The heart of
affected animals is enlarged due to dilation of both ventricles. Clinical signs are caused by systolic dysfunction
and affected individuals die as a result of severe heart insufﬁciency. BDCMP follows an autosomal recessive
pattern of inheritance and the disease-causing locus was mapped to bovine chromosome 18 (BTA18). In the
present study we describe the successful identiﬁcation of the causative mutation in the OPA3 gene located on
BTA18 that was previously reported to cause 3-methylglutaconic aciduria type III in Iraqi-Jewish patients. We
demonstrated conclusive genetic and functional evidence that the nonsense mutation c.343CNT in the bovine
OPA3 gene causes the late-onset dilated cardiomyopathy in Red Holstein cattle.M.H. Braunschweig).
l rights reserved.© 2010 Elsevier Inc. All rights reserved.1. Introduction
Cardiomyopathies are a heterogeneous group of myocardial
diseases. A contemporary classiﬁcation of cardiomyopathies proposed
by Maron et al. [1] divides them into 2 major groups. Primary
cardiomyopathies are diseases predominantly conﬁned to the heart
muscle, whereas secondary cardiomyopathies have myocardial
involvement as a component of a systemic or multiorgan disorder.
Dilated cardiomyopathy is the most common form of cardiomyop-
athy in humans and classiﬁed in the group of mixed primary
cardiomyopathies including familial disease of genetic origin. The
incidence of dilated cardiomyopathy in humans was estimated to be
5.5/100,000 cases a year and it is the major cause of cardiac
transplantation in children [2]. The pathogenesis of primary cardiomy-
opathies is still poorly understood, although during the last two decades
a large number of gene mutations were identiﬁed providing important
new insights into the mechanisms responsible for inherited cardiomy-
opathies and the aetiology of primary cardiomyopathies [3].
Bovine dilated cardiomyopathy (BDCMP) is a terminal myocardial
disease with a common age at onset between 2 and 4 years, although
calves and older cows can also be affected. Clinical signs are mainly ofright sided heart failure due to systolic dysfunction of the heart
muscle. The hallmark lesion is a cardiomegaly with ventricular and
atrial dilation and hypertrophy. Histopathologically, affected hearts
show a mixture of myoﬁber atrophy and hypertrophy, myoﬁber
vacuolation and ﬁbrosis (Figs. 1A–C) [4–6].
BDCMP has been observed worldwide in Holstein–Friesian popula-
tion from the late 1970s and was traced back to a red factor-carrying
Holstein–Friesian bull, ABC Reﬂection Sovereign which strongly
suggests a hereditary nature of the disease [7–9]. More recently, a
recessive mode of inheritance was demonstrated in a purpose-built
pedigree segregating for BDCMP [10]. In Switzerland Red Holstein
genetics was introgressed into the Simmental population since the late
1960s to improve milk performance. These crosses are now referred to
as Fleckvieh breed. BDCMP affects exclusively Fleckvieh and Red
Holstein animals [6,7,11]. The disease caused considerable economical
loss for the beef industry in the 1980s and ﬁrst half of the 1990s. BDCMP
was successfully eliminated from the Fleckvieh population by excluding
suspected carrier bulls frombreeding. Today however, BDCMP cases are
still sporadically diagnosed in Switzerland.
Recently we have ﬁne mapped the BDCMP locus to a 1.0-Mb
interval on BTA18 based on linkage analysis and a combined
homozygosity mapping and association-based strategy [12]. Herein,
we present conclusive genetic and functional evidence, additionally
supported by similarities to data reported from an ENU-induced
mutant mouse model [13] that a nonsense mutation in the OPA3 gene
causes the late-onset dilated cardiomyopathy in Red Holstein cattle.
Fig. 1. Symptoms of BDCMP. (A) Clinical signs of BDCMP consist of congestion of the
jugular veins, subacute oedema within the brisket and abduction of the forelegs
(indicated by arrows). (B) Comparison between normal (on the left) and BDCMP-
affected (on the right) hearts. (C) Histological staining of normal (left) and BDCMP-
affected (right) heart tissues. Haematoxylin–Eosin and Masson Trichrome stainings are
presented on the top and on the bottom, respectively. In both slides of affected tissues
myoﬁber vacuolation andmyoﬁber size variation are visible while transmural ﬁbrosis is
shown in turquoise for the Masson Trichrome staining.
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2.1. DNA isolation
DNA from 507 blood samples was isolated using a Nucleon Bacc2
Kit (GE Healthcare) or a High Pure PCR Template Puriﬁcation Kit
(Roche). DNA from ﬁve parafﬁn-embedded myocardial samples was
isolated and puriﬁed using a DNeasy Blood & Tissue Kit (Qiagen). In
addition, 42 DNA samples were isolated from the interphase
remaining after RNA isolation from heart tissues using the TRIZOL
Reagent (Invitrogen).
2.2. RNA extraction and ﬁrst-strand cDNA synthesis
Total RNA from 42 heart tissues, 9 kidney tissues, 9 lung tissues
and 9 liver tissues was extracted using the TRIZOL Reagent
(Invitrogen). Afterwards, aliquots of 5 μg of the total RNA were
reverse transcribed using a First-Strand cDNA Synthesis Kit (GE
Healthcare).
2.3. Fine mapping of the BDCMP locus and screening of the bovine
vasodilator-stimulated phosphoprotein gene (VASP)
Swiss Fleckvieh animals, 25 BDCMP-affected and 25 controls, were
genotyped with 109 SNP markers located within the previously
described 1.0-Mb interval of interest using standard protocols [12].
Thirteen exons of the bovine VASP gene were deduced based on a
comparison of an annotated bovine sequences (GenBank: NC_007316
and NM_001038110) with a human VASP mRNA counterpart
(GenBank: NM_003370) using Spidey program (http://www.ncbi.
nlm.nih.gov/spidey/). Exons and partial ﬂanking introns were PCR
ampliﬁed with speciﬁc primers using AmpliTaq Gold 360 Master Mix
according to the manufacturer's instructions (Applied Biosystems).
Amplicons were subsequently treated with a rAPid alkaline phospha-
tase (Roche) and exonuclease I (New England Biolabs) and sequenced
from both directions on a ABI 3730 capillary sequencer (Applied
Biosystems) using the BigDye® Terminator Cycling Kit (Applied
Biosystems). Sequencing data were analyzed with Sequencher 4.9
software (Gene Codes).
2.4. Re-sequencing of 240-kb interval and SNP genotyping
The interval of 240 kb was re-sequenced from 37 overlapping
amplicons for one BDCMP-affected animal and one control animal.
Primers were designed using the Primer3 software (http://frodo.wi.
mit.edu/cgi-bin/primer3/). The PCR generated fragments ranging
from 3000 to 11,000 bp were ampliﬁed by means of SequalPrep™
Long PCR Kit (Invitrogen). Contigs were aligned to the corresponding
reference sequence from the bovine genome assembly Btau 4.0 and
analyzed using the Sequencher 4.9 software (Gene Codes). Among all
identiﬁed sequencing variations only unique SNPs for the sequence
from BDCMP-affected animal were considered for further investiga-
tion. For this purpose DNA samples from 22 BDCMP-affected
individuals and 22 controls, Swiss Fleckvieh (n=12) and Simmental
(n=10), respectively were genotyped.
2.5. Structure of the bovine OPA3 gene and mutation identiﬁcation
The human reference OPA3 mRNA variant 1 (GenBank: NM_00101
7989) and variant 2 (GenBank: NM_025136) were used as queries in
cross-species BLAST searches to identify matching bovine EST entries
(GenBank: DV876220, CR550769). Consequently, these ESTs and the
annotated bovine whole genome shotgun sequence (GenBank:
NC_007316) were aligned to the human OPA3mRNA variants using the
Spidey program to predict in silico the bovine OPA3 gene structure. The
precise coding sequence of the bovine OPA3 gene was conﬁrmed
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Gold 360 Master Mix (Applied Biosystems) and by sequencing.
In order to verify the bovine OPA3 gene c.343CNT mutation 33
BDCMP-affected and 35 control animals of Swiss Fleckvieh were
genotyped for the mutation. PCR products surrounding the mutation
were generatedwithprimersOPA3_v2_F 5′-CTGCAGCTCCTCCAGGTC-3′
and OPA3_v2_R 5′-CCTGAACGCACAACCTGAC-3′ and subsequently
sequenced from both directions. DNA samples from different cattle
breeds [Simmental (n=109), Holstein Friesian (n=100), Brown Swiss
(n=121), Herens (n=4), Romagnola (n=2), Chianina (n=4),
Tyrolese Gray Cattle (n=4), Belted Galloway (n=4), Dutch Belted
(n=4), Highland (n=2), Galloway (n=2), Hereford (n=4), Jersey
(n=2), Charolais (n=2), Gelbvieh (n=2), Aubrac (n=1), Salers
(n=1), Angus (n=2) and Limousin (n=1)] were also genotyped to
validate the mutation.
2.6. Expression analysis of the bovine OPA3 gene
We used a TaqMan® assay (Applied Biosystems) to quantify the
expression level of the two OPA3 different transcript variants and
normalized them to two endogenous controls, GAPDH and B2M,
respectively. Primers and probes were designed by Primer Express 3.0
(Applied Biosystems). Three random cDNA samples were pooled and
diluted to obtain a 6 point standard curve. Each sample of the standard
curve was analyzed in triplicate. cDNA samples were diluted in the
ratio of 1 to 5 and analyzed in triplicate using the TaqMan® Gene
Expression Master Kit (Applied Biosystems) on a 7300 Real-Time PCR
System (Applied Biosystems).
Data were analyzed using the S.D.S. v.1.3.1 software according to
guidelines from Applied Biosystems. All conducted statistical analyses
were performed with a SAS Genetics 9.1.3. Software (SAS Institute
Inc., Cary, NC, USA) using a General LinearModel (GLM) procedure. The
GLM procedure was used to test statistical contrasts of bovine OPA3
gene expression levels normalized to the expression levels of two
endogenous controls GAPDH and BM2 between groups.
2.7. Suppression of nonsense-mediated decay
Primary ﬁbroblasts from foetal heart tissues heterozygous for the
OPA3 c.343CNT mutation were grown in DMEM+GlutoMAX™-I
(Gibco) medium to 70% of conﬂuence. In order to test for the presence
of nonsense-mediated mRNA decay (NMD), heart ﬁbroblasts were
exposed to puromycin (200 μg/ml) (SIGMA-ALDRICH) for 18 h
including an untreated control. The OPA3 RNA expression of the two
alleles was analyzed by simply comparing the peak area from
electropherograms of the sequencing reaction.
2.8. Site-directed mutagenesis and cell transfection
The full-length bovine OPA3 cDNA was PCR ampliﬁed using two
primers (5′-ATATATCGGACCGATGGTGGT GGGCGCGTTCCCTATGGC-3′
and5′-ATATATCGGTCCGCTACTTCTTGGGTGAGGATGCTGCCTGGGAC-3)
and cloned into pCI plasmid (Promega).
Site-directed mutagenesis of the c.343CNT mutation was per-
formed with QuickChange Lightning Site-Directed Mutagenesis Kit
(Stratagene). Plasmids were ampliﬁed by PCR using primers containing
the mutation. Afterwards, plasmids were digested with DpnI restriction
enzyme and transformed into E. coli XL10-Gold Ultracompetent cells
[14]. Plasmids were sequenced from both directions to conﬁrm the
presence of the desired mutation. Human 293T kidney cells were
transfected using FuGene® HD Transfection Reagent (Roche) with four
vectors containing appropriate sequences, theWT-OPA3, the MT-OPA3,
the MT-OPA3 followed by an extra stop codon and the empty vector.
Cells were harvested after 24 h and lysed using a RIPA lysis buffer
according to standard protocols.2.9. Western blotting
Subsequently, 30 μl of the supernatants were combined with the
same amount of 2× Laemmli sample buffer (Bio-Rad), boiled at 95 °C
for 5 min and fractionated on 17% SDS polyacrylamide gels under
denaturing conditions. Separated proteins were transferred to
nitrocellulose membranes by electroblotting. The membranes were
blocked with TBS-Tween (25 mM Tris–HCl, pH 7.5, 137 mM NaCl,
3 mM KCl, 0.1% Tween 20) containing 5% of non-fat powdered milk
[15]. Then the membranes were incubated either with a 1:1000
dilution in blocking buffer of a mouse monoclonal anti-HA antibody
(Covance) for 1 h at room temperature or with a 1:700 dilution of a
polyclonal rabbit OPA3 antibody (ProteinTech Group) over night at
4 °C. After series of washings with TBS-Tween, the membranes were
incubated for 1 h at room temperature using a 1:9000 dilution of
secondary antibodies, a polyclonal rabbit anit-mouse immunoglobu-
lins/HRP and a polyclonal goat anti-rabbit immunoglobulins/HRP
(DakoCytomation), respectively. The bound antibodies were detected
after successive TBS-Tween washings' series with the enhanced
chemiluminescence kit (GE Healthcare) and visualized using a camera
LAS300 (Fujiﬁlm Intelligent Dark Box LAS 300). We used the
Qproteome mitochondria isolation kit from Qiagen to isolate
mitochondria from heart tissues as describe in the manual.
3. Results
3.1. Fine mapping of the disease-causing locus on BTA18 and screening
of the bovine VASP gene
We have reported the ﬁne mapping of the BDCMP locus to the 1.0-
Mb interval [12]. To further narrow down this region of interest we
genotyped additional 50 BDCMP-affected and control animals for a
panel of 109 SNP markers. By this approach we identiﬁed chromo-
somes of BDCMP-affected animals that carried recombination events
which together reduced the BDCMP interval to about 290 kb.
Centromeric to this interval a putative candidate, the vasodilator-
stimulated phosphoprotein gene (VASP) was located [16]. By
sequencing all 13 VASP exons and partial ﬂanking introns we
identiﬁed two SNPs. A c.760CNA transversion in exon 7 leads to an
amino acids exchange (p.P254T) whereas a c.830+310ANG transition
is located in the intron 7 of the VASP gene. We genotyped additional
17 BDCMP cases and 17 control animals to investigate the association
between the c.760CNA transversion in exon 7 of the bovine VASP gene.
In total, we found that 23 BDCMP-affected animals were 760AA and 2
were 760C/A, whereas no 760CC genotype was observed. Within the
group of control individuals 12 were 760CC, 9 were 760C/A and 4
were 760AA. Similar results were found for the ANG transition in the
intron 7 of the VASP gene (Table S1). According to the hypothesized
recessive mode of inheritance for BDCMP these mutations are not
causative for BDCMP. Importantly, we identiﬁed two BDCMP-affected
animals which were heterozygous for both mutations in the bovine
VASP gene representing recombination events more telomeric on
BTA18. This resulted in a signiﬁcant reduction of the BDCMP interval
to about 240 kb.
3.2. Re-sequencing of the 240 kb interval and further SNP genotyping
We re-sequenced overlapping PCR amplicons of this 240 kb
BDCMP region of one BDCMP-affected animal and one control animal
and obtained nearly all sequence. The interval extends from 52.89 to
53.13 Mb on BTA18 (Btau 4.0) and contains nine annotated genes
(VASP, OPA3, GPR4, EML2, GIPR, SNRPD2, QPCTL, SIX5 and RSHL1) and
three annotated loci (LOC10014, LOC51367 and LOC79009) (Fig. 2A).
At ﬁrst glance we were not aware of an obvious BDCMP candidate
gene among these genes. Coding sequences of each of these genes
were established by cross-species alignments to the bovine Btau 4.0
Fig. 2. Fine mapping of the BDCMP locus and a positional identiﬁcation of the nonsense mutation in OPA3 gene. (A) Gene content of the 218 kb interval on BTA18. Black boxes
visualize a genomic size of a particular genes and arrows below show direction of the genes. The white box points at a position of the OPA3 gene. (B) Structure of the bovine OPA3
gene and its different transcript variants. Gray boxes represent annotated exons of the gene, while the white box indicates the new-found second exon of the OPA3 transcription
variant 2. (C) The c.343CNT mutation in the bovine OPA3 gene leading to the premature termination codon.
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transcripts with their humanmRNA orthologs. Re-sequencing of all 37
overlapping amplicons with internal speciﬁc primers revealed 230
SNPs. Among them 29 SNPs were unique for the BDCMP-affected
animal and thus considered for further examination. We used a pool
of 22 BDCMP-affected and 22 control animals of Swiss Fleckvieh and
Simmental breeds to evaluate those SNPs. Within the group of
BDCMP-affected animals we included the two individuals that were
heterozygous for the two polymorphisms in the VASP gene. The SNP
analysis revealed that the heterozygosity of these individuals
extended even further to the telomeric site of the VASP gene and
consequently the BDCMP interval could be reduced to 218 kb
(Fig. 2A). We identiﬁed one SNP in the bovine SIX5 gene exon 1
(c.201ANG, synonymous) and another SNP in the bovine DMPK gene
intron 10 (c.1345+680TNC) of which causality for BDCMP was
dismissed based on common alleles between affected and unaffected
animals (Table S1). Further 22 SNPs in the 218 kb interval were not
associated with BDCMP. Finally and most signiﬁcant, three identiﬁed
SNPs (c.343CNT, c.142+17861GNA, c.142+13366GNC) within the
OPA3 gene could not be excluded by this SNP analysis.3.3. BDCMP is caused by the nonsense mutation c.343CNT in the bovine
OPA3 gene
We ﬁne mapped the disease-causing locus to the chromosomal
interval of 218 kb on the telomeric end of BTA18. Within this region
we could successfully exclude all SNPs to be causative for BDCMP
except for three SNPs that are located in the bovine OPA3 gene. One of
these three SNPs, c.142+7861 GNA, was located in intron 1 of the
OPA3 gene and completely associated with the disease phenotype.
However, an in silico analysis using MATCH™ and TFSEARCH software
(http://www.gene-regulation.com, http://www.cbrc.jp/research/db/
TFSEARCH.html) did not indicate that the c.142+17861GNAmutation
abrogates a known transcription factor binding site. Contrary, a
second SNP inOPA3 intron 1, c.142+13366GNC, was in a heterozygous
state in 29 out of 109 controls of Simmental breed and importantly,
one Simmental individual was homozygous for the C allele, which
formally excludes the causality of the c.142+13366C allele for BDCMP
(Table S1).
In human, two mRNA transcript variants of the OPA3 gene are
annotated, whereas in bovine only one ortholog OPA3 mRNA
Fig. 3. In vivo gene expression of the bovine OPA3 gene. OPA3 gene expression was
measured in heart tissues form BDCMP-unaffected (WT, n=11), carriers (n=20) and
BDCMP-affected (MT, n=11) animals and normalized to two housekeeping genesGAPDH
and B2M. The bars represent mean expression level normalized to the corresponding
housekeeping gene for each genotype (A) Relative expression levels of theOPA3 transcript
variant 1 related to GAPDH (black bars) and to B2M (white bars). (B) Expression levels of
the OPA3 transcript variant 2 related to GAPDH (black bars) and to B2M (white bars). The
lines aboveof the eachbar graph indicate either signiﬁcant P valuesor a lack of signiﬁcance
denotedbyNS, for the four contrasts (Kruskal–Wallis rank sum test, two-sided) (I—WTvs.
carrier, II—WT vs. MT, III — carrier vs. MT and IV —WT and carrier vs. MT).
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to the human OPA3mRNA transcript variant 1 (NM_001017989). We
used cross-species alignments with bovine ESTs which enabled us to
establish the second variant of the bovine OPA3mRNA corresponding
to the human OPA3 mRNA transcript variant 2 (GenBank:
NM_025136) and the mouse OPA3 mRNA ortholog (GenBank:
NM_207525) (Fig. 2B). These in silico ﬁndings were experimentally
conﬁrmed using RT-PCR. By this means we were able to demonstrate
that the nonsense mutation c.343CNT (p.Q115X) causing a premature
stop codon is indeed located in the newly identiﬁed exon 2 of the
OPA3 transcript variant 2 (Fig. 2C). The 343TT genotype was
exclusively found in all BDCMP-affected animals of Swiss Fleckvieh
breed (n=33). In the group of 376 control animals, 5 out of 35
individuals of Swiss Fleckvieh and 4 out of 100 individuals of Holstein
Friesian revealed a 343C/T genotype, whereas 367 animals belonging
to other cattle breeds showed exclusively the 343CC genotype.
Furthermore, the mutation perfectly segregated in our purpose-built
pedigree [17]. We argue that the intronic mutation is less likely tocause BDCMP as compared to the nonsense mutation in the OPA3
gene.
3.4. Expression analysis of the bovine OPA3 gene
We quantiﬁed the gene expression of both bovine OPA3 variants in
heart tissues of the right ventricle. Two bovine housekeeping genes,
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) and B2M
(beta-2-microglobulin), were used for data normalization. Calculated
ampliﬁcation efﬁciencies for all investigated genes were N98%.
Relations between expression levels of targets and independent
endogenous controls were estimated by the relative standard curve
method. The analysis of variance revealed a signiﬁcant difference in
OPA3 variant 1 expression level between BDCMP-unaffected (WT for
wild type), carrier and BDCMP-affected (MT for mutant) animals
when normalized to the GAPDH expression level (Pb0.001) but the
difference reached no signiﬁcance when normalized to that of B2M
(P=0.6) although it shows the same tendency (contrast IV, Fig. 3A).
The contrast between genotype groups revealed no signiﬁcant
difference in expression levels of the OPA3 variant 1 between WT
animals and carrier animals (contrast I) when normalized to the
GAPDH (P=0.07). Signiﬁcant differences in gene expression of OPA3
variant 1 were found for the contrasts between WT animals and MT
animals (contrast II) as well as between carriers and MT animals
(contrast III) when normalized to the GAPDH expression levels
(Pb0.001 Pb0.001, respectively). Interestingly, the expression levels
of the OPA3 variant 2 normalized to the expression level of GAPDH
showed signiﬁcant differences between the groups of WT animals,
carriers and MT animals and the contrasts II to IV were highly
signiﬁcant with Pb0.001 whereas the contrast I was signiﬁcant with
Pb0.01 (Fig. 3B). The differences in OPA3 variant 2 expression levels
were, with the exception of contrast I also signiﬁcant when
normalized to the B2M expression level with P=0.05 for contrast II
and Pb0.05 for contrast III, respectively. The contrast between WT
animals and carriers versus MT individuals (contrast IV) was also
signiﬁcant (Pb0.05). The most striking result is that the gene
expression of the mutant OPA3 variant 2 was reduced whereas the
corresponding uncompromised variant 1 was increased in heart
tissues.
OPA3 gene expression levels of variant 1 and 2 normalized to
GAPDH gene expression showed similar expression tendency in
kidney, lungs and liver tissues from three individuals of each OPA3
genotype. Although the differences between genotypes did not reach
statistical signiﬁcance it indicates that OPA3 gene expression of
variant 2 is not only reduced in heart tissues but also in the
abovementioned tissues of BDCMP-affected animals.
3.5. mRNA Nonsense-mediated decay
We assumed that the reduced OPA3 variant 2 expression in the
heart of BDCMP-affected and carrier animals could be due to mRNA
nonsense-mediated decay (NMD). To verify this hypothesis we
treated primary heart ﬁbroblasts from a carrier individual (343C/T)
with puromycin, which is known as a translation inhibitor that
suppresses NMD [18]. Sequencing of PCR products from cDNA
samples from untreated control cells revealed fewer products from
the mutant allele as indicated by the peak areas of cytosine and
thymine in the electropherogram at position c.343 of OPA3 variant 2
(Supplementary Fig. S1A). In contrast, the results from the puromycin
treated cells revealed similar peak areas for the 343C and the mutant
343T alleles (Supplementary Fig. S1B). These results strongly support
the hypothesis that the observed reduction in OPA3 variant 2
transcripts with the nonsense mutation c.343T might be seen in the
light of NMD [18] although transcription levels could still bemeasured
by real-time PCR.
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To investigate OPA3 expression in heart tissue samples, we ﬁrst
generated wild type (WT) controls for assessing OPA3 expression. To
this aim, we constructed mammalian expression vectors encoding the
full-length OPA3 open reading frame. The mutated version (MT) was
generated by introducing the 343T allele (HA-OPA3 MT, 1 stop). In
addition, a mutant with a second stop codon (HA-OPA3 MT, 2 stops)
was constructed in order to verify OPA3 protein expression. All
plasmidswere engineered to bear a supplementary C-terminal HA-tag
sequence to facilitate detection. We thus performed OPA3 Western
blotting analysis on lysates of transfected 293T human cells. We
detected bands for the corresponding molecular weight marker for
WT OPA3 protein and its MT form using anti-HA antibody. We
demonstrated qualitatively in this artiﬁcial system that OPA3 protein
and the truncated form are properly produced in these transfected
cells that overexpressed the bovine OPA3 wild type and mutant
coding sequences, respectively (Supplementary Fig. S2A). A human
OPA3 antibody directed against the region between the 24th to 179th
amino acids of the human OPA3 protein was then tested to verify its
suitability to detect bovine OPA3 protein from these transfected cells.
The target fragment of these 155 amino acids is conserved between
human and bovine and shows 92% of identity. The OPA3 antibody
revealed indeed band corresponding to the WT bovine OPA3 protein
of 20 kDa. Moreover, a subtle band of 12 kDa corresponding to a
truncated OPA3 protein was also detected (Supplementary Fig. S2B).
The pronounced band detected in the samples of WT, MT and empty
vector matches to the human OPA3 protein from the human 293T
kidney cells. It is expected that no bovine WT OPA3 protein will be
detected in the cells transfected with the mutated form since the
c.343CNT mutation in the bovine OPA3 gene leads to a premature stop
codon. To conﬁrm that these ﬁndings are consisting with OPA3
expression in BDCMP-affected heart we performed Western blot
experiments using bovine heart tissues. It was not possible in our
hands to obtain the corresponding signals on heart tissue samples.We
reasoned that it might be more appropriate to validate our in vitro
results on isolated mitochondria because OPA3 protein was consid-
ered to be located in their inner membrane [19] whereas a more
recent study found evidence that OPA3 is present in the outer
membrane of mitochondria [20]. In Supplementary Fig. S2C aWestern
blot of OPA3 protein is shown using mitochondria isolates from heart
tissues of an affected cow, an affected calf and a control animal.
Interestingly, we detected in the WT two bands for OPA3 protein
which is consistent with the existence of the two OPA3 variants in our
gene expression results. A single variant protein was identiﬁed in the
MT sample from an adult cow. We did not obtain a signal that would
indicate a truncated form of OPA3 protein. In addition a band is visible
in themitochondria sample from a calf heart that does not correspond
to the expected size of OPA3 protein. It remains elusive whether
further OPA3 protein variants exist in younger animals. However, by
far the most affected animals were between two and four years of age.
In summary the Western blot analysis on mitochondria isolates
indicates that in bovine WT heart two protein variants are abundant
and in the MT heart only one protein variant is detectable and the
compromised variant 2 is much less present or even absent in
mitochondria. This ﬁnding is in complete agreement with the fact that
the mutation affects variant 2 whereas variant 1 of the OPA3 gene is
still abundant.
4. Discussion
The human OPA3 gene consists of two exons and its transcripts
encode a peptide of 179 amino acids (aa) variant 2 [21]. A proteomic
investigation conducted by Da Cruz et al. [19] indicated the location of
the OPA3 protein in the inner membrane of rodent mitochondria
suggesting that this is also true for other mammals. In a recent studyby Ryu et al. (2010) [20] it was demonstrated that OPA3 is located in
the outer membrane of the mitochondria and its down regulation led
to a highly elongated mitochondria suggesting a function in ﬁssion of
mitochondria. Furthermore, opa3 homozygous null mutant zebraﬁsh
modelling Costeff Syndrome demonstrates a requirement for mito-
chondrial OPA3 to limit 3-hydroxy-3-methylglutarylcoenzyme-de-
rived 3-methylglutaconic acid and to protect the electron transport
chain against inhibitory compounds [22].
The bovine OPA3 gene has also two exons. The gene encodes two
proteins of 191 aa and 186 aa derived from the transcript variant 1 and
the newly identiﬁed transcript variant 2 (HM136903), respectively.
The two OPA3 transcript variants share the same ﬁrst exon but they
differ from the second exon. Nevertheless, sequences of the OPA3
protein variants show an identity of 80% (Supplementary Fig. S3A).
The bovine OPA3 protein variant 2 shares 87% identity with horse, 84%
with human, 86% with chimpanzee and rhesus macaque, 84% with
dog, 79% with mouse and 68% with gray short-tailed opossum. The
OPA3 protein sequences for much more divergent species such as
starlet sea anemone, California purple sea urchin and lancelet show an
identity of 43%, 41% and 46% to the bovine OPA3 protein variant 2. The
p.Q115Xmutation resideswithin a conserved part of the protein and a
wild type glutamine is conserved across the kingdom of Animalia
(Supplementary Fig. S3B).
Initially, the VASP gene was our favoured candidate gene for BDCMP
because Eigenthaler et al. [16] described a function of the murine
Ena-VASP protein in the intercalated disks of cardiac myocytes. Our
sequencing results of this gene revealed two SNPs located in the exon 7
(c.760CNA) and in the intron 7 (c.830+310ANG). However, heterozy-
gous BDCMP-affected animalswere found that allowed to exclude these
mutations to cause the disease. Moreover, we also screened the
PPP1R13L gene (protein phosphatase 1 regulatory inhibitor-subunit 13
like) located in the centromeric of our interval because Simpson et al.
[23] demonstrated that a 7-bp duplication in PPP1R13L exon 6
(c.956_962dup7) causes cardiomyopathy and woolly haircoat syn-
drome in Poll Hereford cattle. However, we did not identify this
mutation in the cohort of BDCMP-affected and control samples and thus
we formally excluded a possibility that this mutation is causative for
BDCMP in Swiss Fleckvieh population.
We successfully identiﬁed the causative mutation for BDCMP by a
classical positional cloning approach. We also developed a direct
genetic test, which facilitates monitoring of BDCMP distribution
within the cattle population. Important support for our ﬁnding came
from a recent study in which an ENU-induced mutant mouse carrying
a c.365TNC mutation in the Opa3 exon 2 was selected in order to
investigate the still unknown function of the OPA3 protein [13].
Homozygous mice for the Opa3 p.122P show severe multi-systemic
diseases including symptoms of type III 3-methylglutaconic aciduria
(MGA type III) (also known as optic atrophy plus syndrome or Costeff
optic atrophy syndrome). An unexpected ﬁnding and rather a side
effect of thesemice generated to studyMGA type III was that they died
before 4 months of age showing marked cardiomyopathy accompa-
nied by interstitial ﬁbrosis, cardiac muscle ﬁber deposits, atrophy and
hypertrophy of residual muscle ﬁbers as well as vacuolation of muscle
ﬁbers [13]. It has been suggested that a molecular effect of this point
mutation would alter the tertiary structure of the OPA3 protein.
Therefore, a disruption ofα-helix and β-sheet conformationmay have
serious consequences for the function of this protein involved in
recessive type III MGA and dominant autosomal dominant optic
atrophy and cataract (ADOAC, OMIM 165300) [13,24,25]. This report
links for the ﬁrst time a mutation in the Opa3 gene of ENU-induced
mutant mice to dilated cardiomyopathy and thus strongly supports
our ﬁnding that the bovine OPA3 nonsense mutation (p.Q115X)
causes BDCMP in cattle. It is noteworthy that a severe dilated
cardiomyopathy is an unprecedented feature of human MGA type III
and ipso facto there is no report showing an immediate causality
between cardiomyopathy and human OPA3 gene mutations. Dilated
57M. Owczarek-Lipska et al. / Genomics 97 (2011) 51–57cardiomyopathy together with skeletal myopathy, shortened struc-
ture and cyclical neutropenia are found in type II MGA (Barth
syndrome, OMIM 302060). However, this is an X-linked disorder
associated with mutations in the taffazin gene [26]. In addition, an
early-onset dilated cardiomyopathy together with non-progressive
cerebellar ataxia, testicular dysgenesis and growth failure are typical
for autosomal recessively inherited type VMGA (OMIM 610198, [27]).
The identiﬁed nonsense mutation (p.Q115X) in exon 2 of the
bovine OPA3 transcript variant 2 demonstrates that as in human OPA3
gene mutations were exclusively found in variant 2. In contrast, no
mutation has been reported for OPA3 variant 1 and a clinical relevance
of this variant remains unknown [28]. The ﬁrst mutation (IVS1-1GNC)
in the OPA3 gene variant 2 was reported to cause 3-methylglutaconic
aciduria (MGA) type III in Iraqi-Jewish patients of the 143CC genotype
[21]. Later another mutation in the OPA3 gene (c.−38ANG) was found
in a single patient from a cohort of 13 patients [29]. Moreover, a
deletion in exon 2 of the OPA3 gene (c.320_337del) was described in a
juvenile Kurdish-Turkish patient affected with MGA type III who was
previouslymisdiagnosedwithMGA type IV [30]. Recently, a MGA type
III patient was found to be homozygous for the nonsense mutation
c.415CNT (p.Q139X) in the OPA3 variant 2 [28]. Furthermore, two
mutations in the human OPA3 gene, c.2277GNA (p.G93S) and
c.313CNG (p.Q105E) were found in patients with a dominant optic
atrophy 3 [24]. It is worth to mention that BDCMP-affected animals
did not show symptoms similar to Costeff syndrome.
Interestingly, the reduced expression of the OPA3 variant 2 seems
to be compensated by an increased expression of the variant 1
suggesting a coupling to NMD alternative splicing. It is unknown
whether the two OPA3 protein variants have similar function and are
interchangeable. However, the imbalance of the two variantsmight be
an explanation for the late-onset of BDCMP.
In conclusion we present for the ﬁrst time a mutation in the OPA3
gene that causes dilated cardiomyopathy and it is suggested that this
gene might also be responsible for some forms of familiar dilated
cardiomyopathies in human. The involvement of OPA3 gene in cases of
cardiomyopathy will enhance the effort to establish its function in the
inner membrane of the mitochondria and might contribute to a better
understanding of this severe disease.
Supplementary data to this article can be found online at
doi:10.1016/j.ygeno.2010.09.005.
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